Shilpa Biologicals Commissions Integrated ADC Manufacturing Facility in India for End-to-End Drug Substance Production

End-to-end antibody-drug conjugate manufacturing has remained a significant gap in India's high-potency biologics infrastructure, a gap Shilpa Biologicals, a subsidiary of Shilpa Medicare, has moved to close with the commissioning of an integrated ADC drug substance facility. The development positions the company among a narrow cohort of Indian CDMOs capable of executing the full ADC manufacturing sequence under a single roof.

ADC production is operationally demanding: it requires coordinated GMP-compliant handling of cytotoxic payloads, linker chemistry, and biological conjugation within containment-controlled environments. Facilities must satisfy high-potency API (HPAPI) handling standards alongside biologics manufacturing requirements, a combination that has historically limited integrated ADC capacity to a handful of Western and Japanese CDMOs. Shilpa's commissioning signals that Indian manufacturers are now building the technical and regulatory infrastructure to compete for this segment of global outsourcing.

For plant heads and QA directors evaluating contract manufacturing options, the facility's integrated design is the operationally relevant detail. Consolidating antibody production, payload synthesis, and conjugation steps within one site reduces inter-site transfer risk, simplifies batch record continuity, and narrows the surface area for contamination events, each a material consideration under 21 CFR Part 211 and ICH Q10 quality system expectations. Supply chain leads sourcing ADC drug substance will note that a domestic Indian option reduces lead-time exposure tied to cross-border logistics for cytotoxic intermediates.

Regulatory affairs teams assessing the facility's readiness for global filing support will be watching for evidence of process validation packages aligned with major health authority expectations, particularly around conjugation yield consistency, linker stability, and drug-to-antibody ratio (DAR) control, which remain focal points in ADC regulatory submissions to the US FDA and EMA.

The scale and inspection readiness of the facility will determine how quickly Shilpa Biologicals can convert commissioning into commercially active CDMo partnerships and support IND or BLA-stage programs for international sponsors.

Source: Media4Growth via Indian Pharma Post, 23 June 2026.